Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01495390 · ClinicalTrials.gov registry record
A Longitudinal Study of Amyotrophic Lateral Sclerosis (ALS) Biomarkers
A clinical trial, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- 139
- Enrollment target
NCT01495390: Completed study, sponsored by Massachusetts General Hospital.
NCT01495390 is a clinical trial that has completed, run by Massachusetts General Hospital. The registered enrollment target is 139 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01495390 has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- 139 participants
- Enrollment target
Study Summary
The purpose of this study is to collect biofluid samples for the banking and usage in ALS research. Through comparison of these samples, the researchers hope to learn more about the underlying cause of ALS, as well as find unique biological markers, which could be used to develop new therapies.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 139 participants |
| Start Date | 2011-11 |
| Est. Completion | 2016-12-31 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01495390
The ClinicalTrials.gov registry entry for NCT01495390 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 139 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT01495390 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01495390 about?
NCT01495390 is a clinical study titled "A Longitudinal Study of Amyotrophic Lateral Sclerosis (ALS) Biomarkers". The purpose of this study is to collect biofluid samples for the banking and usage in ALS research. Through comparison of these samples, the researchers hope to learn more about the underlying cause of ALS, as well as find unique biological markers, which could be used to develop new therapies.
What is the current status of trial NCT01495390?
This trial is currently completed. The enrollment target is 139 participants. The study started on 2011-11. Estimated completion is 2016-12-31.
Who is sponsoring clinical trial NCT01495390?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.